Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1

Interventions

pembrolizumab 24 Radiotherapy 21 Cisplatin 21 Cetuximab 13 Carboplatin 11 Paclitaxel 8 Nivolumab 8 durvalumab 7 Radiotherapy, Intensity-Modulated 6 Docetaxel 6 Fluorouracil 5 Cyclophosphamide 5 zalutumumab 4 Everolimus 4 Amifostine 4 spartalizumab 3 fludarabine 3 epacadostat 3 cemiplimab 3 Ipilimumab 3 Immune Checkpoint Inhibitors 3 Gefitinib 3 Filgrastim 3 Erlotinib Hydrochloride 3 Celecoxib 3 Capecitabine 3 selpercatinib 2 palbociclib 2 fludarabine phosphate 2 bintrafusp alfa protein, human 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Head and Neck Neoplasms × Digoxin × Clear all

NCT02906800 2017-10-19

DIGHANC

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Unknown

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡